BiotechTube

paroxetine

ApprovedCompleted
0 watching 0 views this week🔥 Hot
84
Hype Score

Development Stage

✓
Pre-clinical
✓
Phase 1
✓
Phase 2
✓
Phase 3
5
Approved
Indication / Disease

Premenstrual Dysphoric Disorder

Conditions

Premenstrual Dysphoric Disorder, Premenstrual Syndrome

Trial Timeline

Oct 1, 2000 → Nov 1, 2002

NCT ID
NCT00516113

About paroxetine

paroxetine is a approved stage product being developed by Novo Nordisk for Premenstrual Dysphoric Disorder. The current trial status is completed. This product is registered under clinical trial identifier NCT00516113. Target conditions include Premenstrual Dysphoric Disorder, Premenstrual Syndrome.

Hype Score Breakdown

Clinical
30
Activity
20
Company
9
Novelty
10
Community
12

Clinical Trials (1)

NCT IDPhaseStatus
NCT00516113ApprovedCompleted

Competing Products

5 competing products in Premenstrual Dysphoric Disorder

See all competitors
ProductCompanyStageHype Score
Levonorgestrel/Ethinyl EstradiolPfizerPhase 3
76
Levonorgestrel/Ethinyl EstradiolPfizerPhase 3
76
LevetiracetamUCBPre-clinical
20
Drospirenone and ethinyl estradiol + PlaceboBayerPre-clinical
20
EE20/DRSP(YAZ, BAY86-5300) + PlaceboBayerPhase 3
74

Other Products from Novo Nordisk

Liraglutide 3.0mg + Placebo Oral Tablet + Phentermine 15 MGApproved
84
Liraglutide + SalineApproved
84
Hydrocortisone + PlaceboApproved
84
biphasic insulin aspart + insulin aspartApproved
84
Semaglutide, 1.34 mg/mL + Empagliflozin 25 MGApproved
84